CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

I downgrade Pfizer to 'Strong Sell' as its high dividend yield fails to offset persistent share price weakness and lack of ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

Dividend stocks are a smart way to navigate an uncertain market. Besides generating steady passive income, dividend-paying ...

Trump's trade war has created a carve-out bonanza for industries with political connections and big lobbying budgets.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...